However, further experimental validation that directly evaluates the impact of IFITM3 loss in an immunocompetent mouse model can shed further light on the direct impact of IFNγ-IFITM3 axis mediated from the tumor immune microenvironment on therapeutic resistance in AML. This evidence concerns the gene IFITM3 and acute myeloid leukemia.